Second Phase 3 Study of YERVOY (ipilimumab) in Metastatic Melanoma Meets Primary Endpoint of Overall Survival - Drugs.com MedNews
Links shared publicly online about this topic.
- 239total visits
Second Phase 3 Study of YERVOY (ipilimumab) in Metastatic Melanoma Meets Primary Endpoint of Overall Survival - Drugs.com MedNews
Study 024 Evaluated Newly-Diagnosed Patients Treated with YERVOY at Investigational Dose of 10mg kg in Combination with Dacarbazine vs. Dacarbazine Alone Forty-
View full resource at drugs.com
Tags: Cancer, Skin Cancer, Melanoma, Drug, Phase 3 Clinical Trial
Most Recently Shared on June 6, 2011 at 12:13 pm By:
Second Phase 3 Study of YERVOY (ipilimumab) in Metastatic Melanoma Meets Primary Endpoint of Overall Survi... http://bit.ly/jlNLPz #drug
Advertisement
